[ET Net News Agency, 28 May 2020] UOB Kay Hian lifted its target price for Ali Health
(00241) to HK$21 from HK$17 and maintained its "buy" rating.
The research house has raised its FY21 revenue estimate by 9% to factor in the better
performance in FY20 and large room for penetration in Alibaba's eco-system. It also raises
its FY21 adj. net profit by 30%, considering Ali Health's proven ability in operation
efficiency. (RC)